Navigation Links
Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
Date:11/8/2007

s of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA ... that its common shares have been approved for listing and ... "EPIX". ESSA will begin trading on NASDAQ on ... the TSX Venture Exchange under the symbol "EPI". ... on the NASDAQ, each of the Company,s outstanding special warrants ...
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 /PRNewswire/ ... industry. Because of its leading role in educating thought ... the functions that can heavily influence how well a ... to a new study from research and consulting leader ... Medical Affairs leaders need to focus on are early ...
(Date:7/2/2015)... you head outdoors with your family to enjoy the summer ... Take steps to protect yourself from the sun, bugs and ... Your Skin From the Sun Exposure to ultraviolet ... skin cancer. To protect your skin from UV radiation, stay ... hours. Wear a hat with a wide brim to shade ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3
... ATLANTA, April 23, 2012 ConvaTec, a world-leading developer and ... today announced that the company has donated $10,000 to the ... Wellness that took place at the 25th Annual Symposium ... Atlanta, Georgia from April 19 to April 22, 2012. ...
... Inc., a biotechnology company focused on developing treatments ... that it has moved its corporate headquarters to ... area of Novato, CA.  The relocation will accommodate ... expand operations in the areas of clinical development, ...
Cached Medicine Technology:ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 2ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 3Ultragenyx Relocates Company Headquarters to Support Operational Expansion 2
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... 03, 2015 , ... First Choice Emergency Room , the largest network ... as the new Medical Director of its Frisco facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The Celebrity ... or cocktail dresses similar to those of celebrities will have the opportunity to get ... at checkout. This ensures that people do not have to use coupon codes or ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2
... advisory committee to the U.S. Food and Drug Administration recommended ... used without a prescription. The FDA does not have to ... does. There is no deadline for making a decision. // ... the ability to do both good and harm. Claritin, Allegra ...
... Hypertensive drugs in general have a common side effect- ... plagues people on a widely-used blood pressure medication.// ... treat high blood pressure, heart failure and other cardiac ... inhibitors are troubled by a cough. The side effect ...
... contains polyphenols in the form of flavonoids and its ... properties. Polyphenols protect the cells from damaging// physiological process ... Oxidation produces free radicals these are unstable ... increased amount of them can damage cells resulting in ...
... supplements of a fatty acid found in fish oil halves ... research has found that eating oily fish such as tuna ... caused by a particular type of irregular heartbeat. This study ... a therapy without side effects for heart patients. ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... An Australian psychiatrist has discovered that treating patients with ... Although antipsychotic drugs like risperidone have been shown to ... researchers have suspected for some time that oestrogen can ... version of the disease than men and it usually ...
Cached Medicine News:
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Medicine Products: